The word has a history. In late-nineteenth-century biology it named a theory — that evolution advances in straight lines, pushed by an internal drive toward a predetermined end. That theory is dead, and it deserved to die. Nothing here revives it.
What we mean is orthogonal genesis: form generated under constraint, along the directions the constraints leave open. There is no drive and no destination. A growing shell does not reach toward its shape — it runs out of alternatives. Curvature does not pull development forward; it removes options. Time and gravity and the geometry of the surface do the rest.
That is why the direction is real without being intended. Systems move, and the directions available to them are dictated by forces, not by purpose. Waddington called the biological version canalisation: development running in valleys, buffered against perturbation, directional without being goal-seeking. His epigenetic landscape is a curvature picture. It is the K operator, drawn by a biologist who did not know that is what he was drawing.
Generative science says what physics says: the form is what the constraints permit. Biology may take some time to hear the difference between a system that is pushed and a system that has nowhere else to go. That difference is the whole book.
Dr. Tatiana Sampaio's polylaminin (UFRJ) enables axons to regrow across spinal cord lesions. In a 2024 pre-trial pilot — 8 patients, reported as a medRxiv preprint (10.1101/2024.02.19.24301010) and not peer-reviewed — 6 of 8 patients with complete spinal cord injury regained voluntary motor control. ANVISA authorised a Phase I safety trial in January 2026 (5 patients, acute thoracic injury under 72 hours), which has not yet reported. The mechanism — a placenta-derived molecular scaffold that mimics the embryonic environment and guides axonal regrowth across a glial scar — is, in the language of contact geometry, a Whitney A₁ fold: the same structure proved without sorry in the companion chapter on autophagy and stellar nucleosynthesis. This chapter provides the mathematical spine.
Laminin is an extracellular matrix protein essential to neural development. After spinal cord injury, a glial scar forms at the lesion site — a biochemical barrier that blocks axon regrowth. Polylaminin is laminin that has been polymerised at acidic pH, transforming from a monomer into a scaffold. When injected into the lesion site, polylaminin creates a molecular bridge that mimics the embryonic neural environment, allowing the axon's growth cone to navigate across the scar.
The 2024 medRxiv preprint (Menezes et al.) reports: 8 patients with complete spinal cord injury (zero voluntary motor function below lesion), injected with polylaminin within 6 days of injury. 6 of 8 regained voluntary motor contraction [preliminary — preprint, not peer-reviewed]. 4 were tetraplegic; the most dramatic recovery was Bruno Drummond, walking and descending stairs 7 years after a 2018 injury treated within 24 hours.
| Finding | Result | Status |
|---|---|---|
| Human pilot (acute) | 6/8 patients regained voluntary motor control; complete SCI classification | Published preprint 2024 |
| Animal (chronic) | Dogs paralysed for months recovered walking after polylaminin + chondroitinase | Frontiers Vet Sci, Aug 2025 |
| Rat model (acute) | BBB locomotion score: 4.2→8.8 at 8 weeks post-complete transection | Published (ResearchGate) |
| ANVISA Phase I | 5 volunteers, acute thoracic SCI (<72 hrs), single surgical injection | Authorized Jan 2026 |
| Court-ordered access | ~10 court orders granting compassionate access by Feb 2026 | Ongoing |
V_critical_at_one, V_second_deriv_ne_zero, V_factored.
The dm³ framework identifies four operators that govern self-regulating biological systems: C (compress — select the relevant degrees of freedom), K (curvature — apply nonlinear intensification), F (fold — cross a critical transition), U (unfold — stabilise in the new configuration). The composite G = U ∘ F ∘ K ∘ C is realised on a contact 3-manifold with contact form α = dz − ρ² dθ.
The contact form non-degeneracy (α ∧ dα ≠ 0) is satisfied for ρ > 0 — proved as contactCoeff_neg: the coefficient c(ρ) = −2ρ < 0. The Gronwall stability radius[Ch 10] ε₀ = 1/3 gives the basin of attraction around the new stable configuration. The stability functional Φ(ρ) = ρ² is the mTOR activity squared, verified positive and strictly increasing (Φ_pos, dΦ_pos).
The Coherence Bridge maps biological systems to the dm³ scalar invariants (μ_max, β, κ*). Chapter A added autophagy and triple-alpha. Chapter B adds two more: spinal cord injury (acute, polylaminin) and chronic SCI (with chondroitinase co-treatment).
★ Estimated from Menezes et al. (2024) recovery timeline data. ★★ Estimated from Chize et al. (2025) canine longitudinal trial. Full parameter extraction pending Phase I data.
Polilaminina is not a registered or approved treatment in Brazil. It is in a Phase I safety trial authorised by ANVISA in January 2026 (5 patients). Separately, it is reaching patients nationwide: ANVISA authorised 33 patients under its Programa de Uso Compassivo after the sponsor, Cristália, agreed to donate doses, against 59 judicial decisions as of 11 March 2026, with a later tranche reported at 38. Hospitals including HUOP in Paraná have administered it.
Compassionate use is not approval — it is the pathway that exists because a product is unapproved, reserved for serious conditions with no alternative. ANVISA has no law or regulation changed for polilaminina; it runs a monitoring protocol on these patients to inform future decisions. The Brazilian Academy of Sciences has urged caution, and deaths have occurred among patients who obtained it by court order, with the manufacturer denying any connection.
Precedent worth knowing: in 2016 Congress did pass such a law for another unapproved compound — Lei 13.269/2016, fosfoetanolamina sintética, the "pílula do câncer" — authorising use without ANVISA registration. The AMB challenged it (ADI 5501) and the STF suspended it on 19 May 2016, later ruling it unconstitutional: the state must guarantee safety through technical review, and that is ANVISA's competence, not Congress's by abstract statute. Trials then found no benefit. No equivalent law exists for polilaminina.